Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Carazolol is a potent β1/β2 adrenoceptor antagonist used in the treatment of hypertension. Its affinity for the beta 3-adrenoceptor was determined in Chinese hamster ovary cells transfected with the gene of the human or the murine beta 3-adrenoceptor. Carazolol is recognized with a nanomolar affinity, which positions it among the best ligands for beta 3-adrenoceptors.
ln Vivo |
There have been no notable negative effects reported with calalol (0.01 mg/kg; IM; once) [2].
|
---|---|
Animal Protocol |
Animal/Disease Models: Kivircik sheep, 25-45 kg, non-pregnant [2]
Doses: 0.01 mg/kg Route of Administration: intramuscularinjection, one time Experimental Results: Urea, creatinine, ALT, ALP, GGT, LDH, Ca, P, T.Protein, Mg, copper levels in serum parameters were found to be at normal levels, but serum iron and zinc levels were diminished. |
References | |
Additional Infomation |
Carazolol is a member of carbazoles.
|
Molecular Formula |
C18H22N2O2
|
---|---|
Molecular Weight |
298.3795
|
Exact Mass |
298.168
|
CAS # |
57775-29-8
|
Related CAS # |
Carazolol-d7;1173021-02-7;Carazolol-d7 hydrochloride;1276197-44-4
|
PubChem CID |
71739
|
Appearance |
White to off-white solid powder
|
Density |
1.2±0.1 g/cm3
|
Boiling Point |
531.2±40.0 °C at 760 mmHg
|
Melting Point |
133-137 °C
|
Flash Point |
275.1±27.3 °C
|
Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
Index of Refraction |
1.652
|
LogP |
3.59
|
Hydrogen Bond Donor Count |
3
|
Hydrogen Bond Acceptor Count |
3
|
Rotatable Bond Count |
6
|
Heavy Atom Count |
22
|
Complexity |
350
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
BQXQGZPYHWWCEB-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C18H22N2O2/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16/h3-9,12-13,19-21H,10-11H2,1-2H3
|
Chemical Name |
1-(Carbazol-4-yloxy)-3-(isopropylamino)-2-propanol
|
Synonyms |
BM-51052 CCRIS-1047BM 51052 CCRIS 1047BM51052 CCRIS1047
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~335.14 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3514 mL | 16.7572 mL | 33.5143 mL | |
5 mM | 0.6703 mL | 3.3514 mL | 6.7029 mL | |
10 mM | 0.3351 mL | 1.6757 mL | 3.3514 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.